Opin vísindi

Cohort profile: the Nordic Antireflux Surgery Cohort (NordASCo)

Cohort profile: the Nordic Antireflux Surgery Cohort (NordASCo)

Title: Cohort profile: the Nordic Antireflux Surgery Cohort (NordASCo)
Author: Maret-Ouda, John
Wahlin, Karl
Artama, Miia
Brusselaers, Nele
Färkkilä, Martti
Lynge, Elsebeth
Mattsson, Fredrik
Pukkala, Eero
Romundstad, Pål
Tryggvadottir, Laufey   orcid.org/0000-0001-8067-9030
... 2 more authors Show all authors
Date: 2017-06
Language: English
Scope: e016505
University/Institute: Háskóli Íslands
University of Iceland
School: Heilbrigðisvísindasvið (HÍ)
School of Health Sciences (UI)
Department: Faculty of Medicine (UI)
Læknadeild (HÍ)
Series: BMJ Open;7(6)
ISSN: 2044-6055
DOI: 10.1136/bmjopen-2017-016505
Subject: Meltingarfærasjúkdómar; Krabbamein
URI: https://hdl.handle.net/20.500.11815/427

Show full item record


Maret-Ouda, J., Wahlin, K., Artama, M., Brusselaers, N., Färkkilä, M., Lynge, E., . . . Lagergren, J. (2017). Cohort profile: the Nordic Antireflux Surgery Cohort (NordASCo). BMJ Open, 7(6). doi:10.1136/bmjopen-2017-016505


Purpose To describe a newly created all-Nordic cohort of patients with gastro-oesophageal reflux disease (GORD), entitled the Nordic Antireflux Surgery Cohort (NordASCo), which will be used to compare participants having undergone antireflux surgery with those who have not regarding risk of cancers, other diseases and mortality. Participants Included were individuals with a GORD diagnosis recorded in any of the nationwide patient registries in the Nordic countries (Denmark, Finland, Iceland, Norway and Sweden) in 1964–2014 (with various start and end years in different countries). Data regarding cancer, other diseases and mortality were retrieved from the nationwide registries for cancer, patients and causes of death, respectively. Findings to date The NordASCo includes 945 153 individuals with a diagnosis of GORD. Of these, 48 433 (5.1%) have undergone primary antireflux surgery. Median age at primary antireflux surgery ranged from 47 to 52 years in the different countries. The coding practices of GORD seem to have differed between the Nordic countries. Future plans The NordASCo will initially be used to analyse the risk of developing known or potential GORD-related cancers, that is, tumours of the oesophagus, stomach, larynx, pharynx and lung, and to evaluate the mortality in the short-term and long-term perspectives. Additionally, the cohort will be used to evaluate the risk of non-malignant respiratory conditions that might be caused by aspiration of gastric contents.


This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Files in this item

This item appears in the following Collection(s)